Analyst Scoreboard: 6 Ratings For Sotera Health
6 analysts have shared their evaluations of Sotera Health (NASDAQ:SHC) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.92, a high estimate of $20.00, and a low estimate of $15.50. This upward trend is apparent, with the current average reflecting a 10.28% increase from the previous average price target of $16.25.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of Sotera Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Donnelly | Citigroup | Lowers | Buy | $16.00 | $18.00 |
| David Windley | Jefferies | Raises | Buy | $15.50 | $15.00 |
| Sean Dodge | RBC Capital | Maintains | Outperform | $20.00 | - |
| Sean Dodge | RBC Capital | Maintains | Outperform | $20.00 | - |
| Luke Sergott | Barclays | Raises | Overweight | $19.00 | $17.00 |
| Luke Sergott | Barclays | Raises | Overweight | $17.00 | $15.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sotera Health. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sotera Health compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sotera Health's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sotera Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Sotera Health analyst ratings.
Discovering Sotera Health: A Closer Look
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Breaking Down Sotera Health's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Sotera Health's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 23.31%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sotera Health's net margin excels beyond industry benchmarks, reaching 12.49%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sotera Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sotera Health's ROA stands out, surpassing industry averages. With an impressive ROA of 1.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sotera Health's debt-to-equity ratio surpasses industry norms, standing at 5.24. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.